Rank |
Status |
Study |
1 |
Recruiting
|
Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease
Conditions: |
Arterial Hypertension; Chronic Renal Insufficiency |
Intervention: |
Procedure: Renal denervation |
Outcome Measures: |
The changes of eGFR by MDRD; Changes in proteinuria (Microalbuminuria) in 6 months; Changes in the value of Cystatin C; Time to the development of end-stage Renal disease (ESRD)/Hemodialysis; combined Renal endpoint; Total mortality; The total cardiovascular mortality; total Renal mortality; changes in blood pressure; •Changes in concentration of Blood urea Nitrogen (BUN) , creatinine in 6 months, 3 years; albumin-creatine ratio; changes in cardiac structure and function; the changes in Renal resistive index |
|
2 |
Recruiting
|
Renal Sympathetic Modification in Patients With Chronic Renal Failure
Condition: |
Chronic Renal Failure |
Intervention: |
Procedure: Renal sympathetic modification |
Outcome Measures: |
the incident of uremia and dialysis requirement; serum creatinine increases into multiples in 1 month follow-up; effect of urine microalbumin, urine microalbumin/creatinine, serum creatinine, or 24 hrs urine protein value; incidence of composite cardiovascular events |
|
3 |
Recruiting
|
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiply Myeloma and Impaired Renal Function (POM Renal)
Conditions: |
Multiple Myeloma; Renal Impairment |
Interventions: |
Drug: 4 mg Oral POM + 40 mg Oral DEX; Drug: 2 mg Oral POM + 40 mg Oral DEX |
Outcome Measures: |
PK-Area under the plasma concentration time curve (AUC); PK-Time to maximum plasma concentration (Cmax); PK-Apparent total body clearance (CL/F); PK-Renal clearance (CLr); PK-Apparent volume of distribution (V/F); PK-Effective terminal half-life (T1/2); Number of participants with adverse events (AEs); Number of participants alive; Time to response; Duration of response |
|
4 |
Recruiting
|
Renal Hypothermia During Partial Nephrectomy
Conditions: |
Renal Impairment; Kidney Diseases; Urologic Diseases; Cancer; Hypothermia; Kidney Cancer |
Intervention: |
Procedure: Renal hypothermia |
Outcome Measures: |
Renal function; Difference in affected Renal function |
|
5 |
Not yet recruiting
|
Immunotherapy Study for Metastatic Renal Cell Cancer
Conditions: |
Metastatic Renal Cell Carcinoma; Metastatic Clear-cell Renal Cancer; Recurrent Renal Cell Carcinoma; Refractory Renal Cell Carcinoma; Metastatic Kidney Cancer |
Intervention: |
Biological: HyperAcute®-Renal (HAR) Immunotherapy |
Outcome Measures: |
Toxicity; Immunological Correlative Studies; Progression-Free Survival |
|
6 |
Recruiting
|
Renal Sympathetic Denervation in Patients With Chronic Kidney Disease and Resistant Hypertension
Condition: |
Chronic Kidney Disease |
Interventions: |
Procedure: RSD; Drug: medicine |
Outcome Measures: |
All-cause mortality, doubling of the serum creatinine level or end-stage Renal disease; Urinary protein excretion and Renal function; Blood pressure; Blood sugar; Cardiac function and structure; Arrhythmia; Pulse wave velocity; Life quality; Rehospitalization rate |
|
7 |
Unknown †
|
A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Third Parties
Conditions: |
Kidney Neoplasms; Renal Insufficiency; Renal Replacement Therapy |
Intervention: |
Procedure: Restored Kidney Transplant Between Third Parties |
Outcome Measure: |
Evaluation of curative efficacy (Renal function and QOL) and safety (side effects, complications or occurence of Renal cancer) after Renal transplantation with restored donor kidneys to third party recipients |
|
8 |
Unknown †
|
A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members
Conditions: |
Kidney Neoplasm; Kidney Stone; Ureteral Tumor; Ureteral Stricture; Renal Insufficiency |
Intervention: |
Procedure: Restored Kidney Transplant Between Family Members |
Outcome Measure: |
Evaluation of curative efficacy (Renal function and QOL) and safety (side effects, complications) after Renal transplantation with restored kidneys between family members |
|
9 |
Recruiting
|
Modalities of Renal Replacement Therapy in Pediatric Acute Kidney Injury
Condition: |
Kidney Failure, Acute |
Intervention: |
Procedure: acute extra Renal replacement therapy |
Outcome Measures: |
extra Renal replacement therapy; Current incidence; etiologies; Risk factors of mortality and non recovery of the Renal function |
|
10 |
Recruiting
|
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
Conditions: |
Multiple Myeloma; End Stage Renal Disease |
Interventions: |
Drug: Cyclophosphamide, anti-thymocyte globulin; Procedure: Kidney transplant; Radiation: Thymic irradiation; Procedure: Bone marrow transplant from a related donor |
Outcome Measures: |
Remission status of multiple myeloma; Renal allograft acceptance and ability to discontinue immunosuppressive therapy; Graft versus host disease (GVHD); Opportunistic infections; T cell recovery and immune reconstitution |
|
11 |
Recruiting
|
A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced Ultrasound (US) in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy
Condition: |
Kidney Cancer |
Interventions: |
Procedure: Contrast-enhanced Ultrasound; Drug: Perflutren lipid |
Outcome Measures: |
Feasibility of using contrast-enhanced ultrasound in diagnosing Renal malignancy in patients with known Renal disease (Cohort 1) and in patients with a risk factor for Renal malignancy diagnosed with suspicious or indeterminate lesions (Cohort 2); Feasibility of comparing the sensitivity and specificity of contrast enhanced ultrasound to traditional imaging techniques (CT and MRI) in detecting Renal lesions in patients already diagnosed with a Renal malignancy |
|
12 |
Not yet recruiting
|
Renal Denervation in Patients With Chronic Heart Failure
Conditions: |
Chronic Heart Failure; Cardio-Renal Syndrome |
Intervention: |
Device: Renal denervation (Symplicity™) |
Outcome Measures: |
Safety of Renal denervation with the Symplicity Catheter System with special consideration of clinically significant periprocedural adverse events in CHF patients; Physiologic response to Renal denervation: ventricular function; Physiologic Response to Renal denervation: Renal function; Physiologic Response to Renal denervation: symptomatology/Quality of Life; Physiologic Response to Renal denervation: additional parameters |
|
13 |
Recruiting
|
Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx)
Conditions: |
Obstructive Sleep Apnea; Overhydration; End Stage Renal Disease; Renal Transplantation |
Intervention: |
Procedure: Renal transplantation |
Outcome Measures: |
Reduction of the obstructive sleep apnea severity; Reduction in nocturnal leg fluid volume shift between the legs and the neck; Relationship between overhydration, leg fluid volume shift, ankle and neck circumference and the severity of obstructive sleep apnea; Change in the severity of the periodic limb movement disorder (PLMD); Change in the severity of central sleep apnea |
|
14 |
Recruiting
|
Study of Catheter Based Renal Denervation Therapy in Hypertension
Conditions: |
Resistant Hypertension; Renal Denervation; Ambulatory Blood Pressure; Renal Function |
Interventions: |
Procedure: Renal angiography followed by Renal sympathetic denervation; Procedure: Renal angiography alone |
Outcome Measures: |
glomerular filtration rate; Ambulatory systolic and diastolic blood pressure; Baroreflex sensitivity; Biological markers of acute kidney injury |
|
15 |
Recruiting
|
Influence of Catheter-based Renal Denervation in Diseases With Increased Sympathetic Activity
Conditions: |
Hypertension; Heart Failure; Chronic Kidney Disease; Diabetes; Heart Rhythm Disorders |
Interventions: |
Device: Renal denervation with Symplicity Flex Medtronic/Ardian; Device: Renal denervation with EnligHTN St. Jude Medical; Device: Renal denervation with Paradise Recor; Device: Renal denervation with V2 Vessix |
Outcome Measures: |
Safety and efficacy of Renal denervation; Effect of Renal denervation on different organ systems. |
|
16 |
Recruiting
|
Renal Denervation for Treatment of Resistant Hypertension in Patients With Chronic Kidney Disease
Conditions: |
Hypertension; Chronic Kidney Disease |
Intervention: |
Procedure: Renal denervation |
Outcome Measures: |
Blood pressure measurements; Renal function |
|
17 |
Not yet recruiting
|
Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study)
Condition: |
Renal Artery Stenosis |
Interventions: |
Drug: Optimal medical therapy; Procedure: revascularization |
Outcome Measures: |
Glomerular filtration rate in the ischemic kidney after revascularization by means of percutaneous Renal angioplasty (PTRAS) or optimal medical treatment.; Lowering blood pressure after revascularization by means of percutaneous Renal angioplasty (PTRAS) or optimal medical treatment.; Preserving overall Renal function after revascularization by means of percutaneous Renal angioplasty (PTRAS) or optimal medical treatment.; Regression of damage in the target organs of hypertension, including cardiac hypertrophy, microalbuminuria and aortic stiffness after revascularization by means of percutaneous Renal angioplasty (PTRAS) or optimal medical treatment. |
|
18 |
Not yet recruiting
|
Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects
Conditions: |
Renal Impairment; Healthy |
Intervention: |
Drug: CKD-501 |
Outcome Measures: |
The pharmacokinetic( Cmax, AUCt ) of lobeglitazone(CKD-501) Between Renal Impaired patients and Normal Renal function subjects; The pharmacokinetic( Cmax, AUCt ) of main metabolites(M7) of CKD-501 Between Renal Impaired patients and Normal Renal function subjects |
|
19 |
Recruiting
|
Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
Conditions: |
Autosomal Dominant Polycystic Kidney Disease; Hypertension |
Interventions: |
Procedure: Renal sympathetic denervation; Drug: antihypertensive drugs |
Outcome Measures: |
office-based measurements of systolic blood pressure; 24-hour systolic blood pressure by ambulatory blood pressure monitoring (ABPM); Incidence of office systolic blood pressure reduction; office diastolic blood pressure; number and dosage of blood pressure tablets; estimated Glomerular Filtration Rate(eGFR); albuminuria; total kidney volume (TKV); pain; procedure-related complications at femoral puncture site; Renal artery lesion; New Renal artery stenosis; Embolic events; hypotension; hypertension.; acute kidney injury; total cyst volume (TCV) |
|
20 |
Recruiting
|
Nephronic Reduction After Neonatal Acute Renal Failure in Preterm
Condition: |
Neonatal Acute Renal Failure in Preterm |
Interventions: |
Other: Renal echography; Other: Blood sampling; Other: collection of an urine sample; Other: Blood pressure measurement |
Outcome Measures: |
microalbuminuria; measurement of blood pressure; measurement of length and volume of kidney by Renal echography; creatinine clearance; calciuria; sodium clearance |
|